This site is intended for healthcare professionals
News

FDA approves Cyramza + erlotinib for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.- Eli Lilly

Read time: 1 mins
Last updated:1st Jun 2020
Published:31th May 2020
Condition: NSCLC / EGFR
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest